Donor-versus-no donor analysis of clinical outcome at 5 years after remission in 683 patients
. | FLT3/ITD- . | . | . | FLT3/ITD+ . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Donor . | No donor . | OR (95% CI) . | Donor . | No donor . | OR (95% CI) . | OR (95% CI) . | Het P* . | |||||
| Patients | 205 | 296 | — | 68 | 114 | — | — | — | |||||
| TRM | 23% | 16% | 1.60 (1.03-2.49) | 32% | 11% | 2.91 (1.22-6.97) | 1.81 (1.22-2.68) | .2 | |||||
| RR | 30% | 51% | 0.70 (0.53-0.92) | 50% | 75% | 0.59 (0.40-0.87) | 0.66 (0.53-0.83) | .5 | |||||
| DFS | 46% | 41% | 0.88 (0.70-1.11) | 34% | 22% | 0.77 (0.54-1.09) | 0.84 (0.69-1.02) | .5 | |||||
| OS | 54% | 49% | 0.90 (0.71-1.16) | 43% | 31% | 0.75 (0.52-1.09) | 0.85 (0.70-1.05) | .4 | |||||
. | FLT3/ITD- . | . | . | FLT3/ITD+ . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Donor . | No donor . | OR (95% CI) . | Donor . | No donor . | OR (95% CI) . | OR (95% CI) . | Het P* . | |||||
| Patients | 205 | 296 | — | 68 | 114 | — | — | — | |||||
| TRM | 23% | 16% | 1.60 (1.03-2.49) | 32% | 11% | 2.91 (1.22-6.97) | 1.81 (1.22-2.68) | .2 | |||||
| RR | 30% | 51% | 0.70 (0.53-0.92) | 50% | 75% | 0.59 (0.40-0.87) | 0.66 (0.53-0.83) | .5 | |||||
| DFS | 46% | 41% | 0.88 (0.70-1.11) | 34% | 22% | 0.77 (0.54-1.09) | 0.84 (0.69-1.02) | .5 | |||||
| OS | 54% | 49% | 0.90 (0.71-1.16) | 43% | 31% | 0.75 (0.52-1.09) | 0.85 (0.70-1.05) | .4 | |||||
OR indicates odds ratio; CI, confidence intervals; TRM, treatment-related mortality; RR, relapse risk; DFS, disease-free survival; OS, overall survival; —, not applicable.
Heterogeneity P values (Het P) are for the interaction between donor or no donor and FLT3/ITD status